Figure 1.
(A) Disease-free survival (DFS) and (B) overall survival (OS) by vascular endothelial growth factor (VEGF) expression among patients with hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-positive, HER2-positive and triple-negative breast cancer. High VEGF expression was significantly associated with lower OS (P=0.03). However, the correlation between VEGF expression and DFS was not significant (P=0.20).